EXG-5003 / Elixirgen Therap - LARVOL DELTA

A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2. (PubMed, Vaccines (Basel)) - "At the 12-month follow-up, participants who had received an approved mRNA vaccine (BNT162b2 or mRNA-1273) >1 month after receiving the second dose of EXG-5003 showed higher cellular responses compared with equivalently vaccinated participants in the placebo group. The findings suggest a priming effect of EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines."

Journal • P1/2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

EXG-5003-J01: Safety and Immunogenicity of EXG-5003 (clinicaltrials.gov) - P1/2 | N=40 | Completed | Sponsor: Fujita Health University | Recruiting ➔ Completed | N=60 ➔ 40

Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD40LG • CD8 • GZMB • IL2 • IL4 • IL6 • LAMP2

Safety and Immunogenicity of EXG-5003 (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Fujita Health University; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD40LG • CD8 • GZMB • IL2 • IL4 • IL6

Safety and Immunogenicity of EXG-5003 (clinicaltrials.gov) - P1/2; N=60; Not yet recruiting; Sponsor: Fujita Health University

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD40LG • CD8 • GZMB • IL2 • IL4 • IL6